secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0000950170-24-092756
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tyra Biosciences Q2 net loss $18.7M; cash remains $373.8M; IND cleared for TYRA-430; ACH IND on track
--------------------------------------------------------------------------------

- Q2 net loss $18.7M ($13.3M in Q2 2023); R&D $18.0M; cash $373.8M, runway through at least 2026.
- FDA cleared IND for TYRA-430 (FGFR4/3 biased inhibitor) for Phase 1 in HCC and other solid tumors.
- TYRA-300: preclinical proof-of-concept in hypochondroplasia; ACH IND submission on track for 2H24.
- CMO Hiroomi Tada to depart by year-end; external search underway; S&T Committee guiding transition.
- SURF301 Phase1 initial results for TYRA-300 expected at a scientific congress in 2H24.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000095017024092756/0000950170-24-092756-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000095017024092756/tyra-20240807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-092756

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer